BC-3195

N/A

Report date: 2026/03/16 20:01:47

Base Information

Drug NameBC-3195

Drug Alias NameBC3195BC-3195

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionCadherin 3 inhibitorsTubulin polymerisation inhibitorsTubulin inhibitors

TargetsCadherin 3Tubulin

Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesWuxi BioCity

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuxi BioCity

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm Metastasis

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A